Keywords
Alzheimer’s disease
Memantine hydrochloride
Donepezil hydrochloride
Submitted : 2025-01-18
Accepted : 2025-02-02
Published : 2025-02-17
Abstract
Objective: To explore the clinical efficacy of sodium oligomannate capsules combined with memantine hydrochloride and donepezil hydrochloride in the treatment of moderate Alzheimer’s disease (AD) and analyze its impact on cognitive function. Methods: Eighty patients with moderate AD admitted to the neurology outpatient clinic of our hospital from June 2021 to December 2022 were selected as the study subjects and randomly divided into a study group and a control group, each with 40 patients. The control group was treated with oral memantine hydrochloride and donepezil hydrochloride, while the study group was additionally treated with oral sodium oligomannate capsules for 24 weeks. The scores of neuropsychological scales [Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE)], and Activities of Daily Living (ADL) scale were compared before and after treatment. Additionally, the levels of homocysteine (Hcy), central nervous system-specific protein (S100-β), interleukin (IL)-6, and tumor necrosis factor (TNF)-α were measured in both groups, and the treatment effects and adverse reactions were compared. Results: After 24 weeks of treatment, the MMSE, MoCA, and ADL scores of both groups were significantly higher than those before treatment (P < 0.05). Compared with the control group after 24 weeks of treatment, the study group had significantly higher MMSE, MoCA, and ADL scores (P < 0.05), and significantly lower levels of Hcy, IL-6, and TNF-α (P < 0.05). Both the study group and the control group showed reduced levels of Hcy, IL-6, and TNF-α after 24 weeks of treatment compared to before (P < 0.05), but there was no significant change in S100-β levels (P > 0.05). Conclusion: The combination of sodium oligomannate capsules, memantine hydrochloride, and donepezil hydrochloride is effective in the treatment of moderate AD. It can improve the cognitive function and daily living abilities of patients with dementia, enhancing their quality of life.
References
Liu S, 2022, Mechanism of Hyperbaric Oxygen Therapy in the Treatment of Alzheimer’s Disease. Journal of Jilin Medical College, 43(6): 432–433.
He B, Zhong F, Wang Y, et al., 2023, Research Progress on Strength Exercise Improving Learning and Memory Abilities in Alzheimer’s Disease. Chinese Journal of Sports Medicine, 42(3): 248–253.
Lee BN, Wang J, Hall MA, et al., 2024, Sex Modifies Effects of Imaging and CSF Biomarkers on Cognitive and Functional Outcomes: A Study of Alzheimer’s Disease. Neurobiol Aging, (133): 67–77.
Shi L, Liu Q, Qian X, et al., 2022, Efficacy of Sodium Oligomannate Combined with Donepezil in the Treatment of Mild Alzheimer’s Disease. Chinese Journal of Geriatrics, 42(19): 4695–4698.
Fan S, Su Y, Ma L, 2019, Observation on the Effect of Galantamine Combined with Memantine Hydrochloride in the Treatment of Alzheimer’s Disease. Chinese Journal of Practical Medicine, 46(1): 105–108.
Xing M, 2023, Improvement of Acutely Progressive Alzheimer’s Disease After Percutaneous Coronary Intervention with Sodium Oligomannate: A Case Report. International Journal of Geriatrics, 44(1): 121–124.
Gao J, Wang W, 2021, Sodium Oligomannate Improves Cognitive Function, Behavioral and Psychiatric Symptoms, and Life Function in a Patient with Alzheimer’s Disease After Ovarian Cancer Surgery. Chinese Journal of New Drugs and Clinical Remedies, 40(11): 797–800.
Huang Y, Tan H, Li R, et al., 2023, Research Progress on Clinical Studies of Alzheimer’s Disease Drugs. Chinese Journal of Neuromedicine, 22(8): 849–855.
Li H, Yu X, Wang H, et al., 2023, Study on the Relationship Between AD7c-NTP, ApoE Alleles, and Cognitive Function in Patients with Alzheimer’s Disease and Its Prodromal Stage. Chinese Journal of Neuromedicine, 22(5): 470–475.
Huang Y, Yu J, 2003, Targeted Aβ Disease-Modifying Therapy for Alzheimer’s Disease: The Dawn of a New Era. Chinese Journal of Neurology, 56(9): 959–964.
Hui T, Lin X, Liu H, 2020, Clinical Study on the Treatment of Mild to Moderate Alzheimer’s Disease with Dihuang Yinzi Combined with Donepezil Hydrochloride Tablets. International Journal of Traditional Chinese Medicine, 42(8): 745–749.
Wang L, Yang J, Wang T, et al., 2023, Study on the Mechanism of Sodium Oligomannate in Improving Cognitive Impairment and Reducing Neuroinflammation in Alzheimer’s Disease. Journal of Hebei Medical University, 44(6): 629–639.
Zhang LF, Zhang YP, Lin PX, et al., 2022, Efficacy and Safety of Sodium Oligomannate in the Treatment of Alzheimer’s Disease. Pak J Pharm Sci, 35(3): 741–745.
Kincaid HJ, Nagpal R, Yadav H, 2021, Diet-Microbiota-Brain Axis in Alzheimer’s Disease. Ann Nutr Metab, 77(Suppl 2): 21–27.
Jiang J, Shi H, Jiang S, et al., 2023, Nutrition in Alzheimer’s Disease: A Review of an Underappreciated Pathophysiological Mechanism. Sci China Life Sci, 66(10): 2257–2279.
Song D, Liu B, Zhong Y, et al., 2022, Clinical Efficacy and Safety of Sodium Oligomannate Combined with Donepezil Hydrochloride in the Treatment of Dementia. Alzheimer’s Disease and Related Diseases, 5(4): 295–299.
Xiao S, Chan P, Wang T, et al., 2021, A 36-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial of Sodium Oligomannate for Mild-to-Moderate Alzheimer’s Dementia. Alzheimers Res Ther, 13(1): 62.